Abstract
Animal testing has made a significant and unequalled contribution to important discoveries and advancements in the fields of research, medicine, vaccine development, and drug discovery. Each year, millions of animals are sacrificed for various experiments, and this is an ongoing process. However, the debate on the ethical and sensible usage of animals in in vivo experimentation is equally important. The need to explore and adopt newer alternatives to animals so as to comply with the goal of reduce, refine, and replace needs attention. Besides the ever-increasing debate on ethical issues, animal research has additional drawbacks (need of trained labour, requirement of breeding area, lengthy protocols, high expenses, transport barriers, difficulty to extrapolate data from animals to humans, etc.). With this scenario, the present review has been framed to give a comprehensive insight into the possible alternative options worth exploring in this direction especially targeting replacements for animal models of bacterial infections. There have been some excellent reviews discussing on the alternate methods for replacing and reducing animals in drug research. However, reviews that discuss the replacements in the field of medical bacteriology with emphasis on animal bacterial infection models are purely limited. The present review discusses on the use of (a) non-mammalian models and (b) alternative systems such as microfluidic chip–based models and microdosing aiming to give a detailed insight into the prospects of these alternative platforms to reduce the number of animals being used in infection studies. This would enlighten the scientific community working in this direction to be well acquainted with the available new approaches and alternatives so that the 3R strategy can be successfully implemented in the field of antibacterial drug research and testing.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Availability of data and material
All the data pertaining the above study is available within the manuscript.
References
Aballay A, Yorgey P, Ausubel FM (2000) Salmonella typhimurium proliferates and establishes a persistent infection in the intestine of Caenorhabditis elegans. Curr Biol 10:1539–1542. https://doi.org/10.1016/s0960-9822(00)00830-7
Adonizio A, Leal SM, Ausubel FM, Mathee K (2008a) Attenuation of Pseudomonas aeruginosa virulence by medicinal plants in a Caenorhabditis elegans model system. J Med Microbiol 57:809–813. https://doi.org/10.1099/jmm.0.47802-0
Adonizio A, Kong KF, Mathee K (2008b) Inhibition of quorum sensing controlled virulence factor production in Pseudomonas aeruginosa by South Florida plant extracts. Antimicrob Agents Chemother 52:198–203. https://doi.org/10.1128/AAC.00612-07
Ahamefule CS, Ezeuduji BC, Ogbonna JC, Moneke AN, Ike AC, Jin C, Wang B, Fang W (2021) Caenorhabditis elegans as an infection model for pathogenic mold and dimorphic fungi: applications and challenges. Front Cell Infect Microbiol 11:751947. https://doi.org/10.3389/fcimb.2021.751947
Akhtar A (2015) The flaws and human harms of animal experimentation. Camb Q Healthc Ethics 24(4):407–419. https://doi.org/10.1017/S0963180115000079
Allegra E, Titball RW, Carter J, Champion OL (2018) Galleria mellonella larvae allow the discrimination of toxic and non-toxic chemicals. Chemosphere 198:469–472. https://doi.org/10.1016/j.chemosphere.2018.01.175
Arora T, Mehta AK, Joshi V, Mehta KD, Rathor N, Mediratta PK, Sharma KK (2011) Substitute of animals in drug research: an approach towards fulfillment of 4R’s. Indian J Pharm Sci 73(1):1–6. https://doi.org/10.4103/0250-474X.89750
Asai M, Li Y, Khara JS, Robertson BD, Langford PR, Newton SM (2019) Galleria mellonella: an infection model for screening compounds against the Mycobacterium tuberculosis complex. Front Microbiol 10:2630. https://doi.org/10.3389/fmicb.2019.02630
Asai M, Li Y, Newton SM, Robertson BD, Langford PR (2023) Galleria mellonella-intracellular bacteria pathogen infection models: the ins and outs. FEMS Microbiol Rev 10;47(2):fuad011. https://doi.org/10.1093/femsre/fuad011
Asai M, Li Y, Spiropoulos J, Cooley W, Everest DJ, Kendall SL, Martín C, Robertson BD, Langford PR, Newton SM (2022) Galleria mellonella as an infection model for the virulent Mycobacterium tuberculosis H37Rv. Virulence 13(1):1543–1557. https://doi.org/10.1080/21505594.2022.2119657
Aziz AUR, Geng C, Fu M, Yu X, Qin K, Liu B (2017) The role of microfluidics for organ on chip simulations. Bioengineering (basel) 4(2):39. https://doi.org/10.3390/bioengineering4020039
Baddal B, Marrazzo P (2021) Refining host-pathogen interactions: organ-on-chip side of the coin. Pathogens 10(2):203. https://doi.org/10.3390/pathogens10020203
Badyal DK, Desai C (2014) Animal use in pharmacology education and research: the changing scenario. Indian J Pharmacol 46(3):257–265. https://doi.org/10.4103/0253-7613.132153
Beeton ML, Alves DR, Enright MC, Jenkins AT (2015) Assessing phage therapy against Pseudomonas aeruginosa using a Galleria mellonella infection model. Int J Antimicrob Agents 46(2):196–200. https://doi.org/10.1016/j.ijantimicag.2015.04.005
Bhise NS, Ribas J, Manoharan V, Zhang YS, Polini A, Massa S, Dokmeci MR, Khademhosseini A (2014) Organ-on-a-chip platforms for studying drug delivery systems. J Control Release 190:82–93. https://doi.org/10.1016/j.jconrel.2014.05.004
Bolm M, Jansen WT, Schnabel R, Chhatwal GS (2004) Hydrogen peroxide-mediated killing of Caenorhabditis elegans: a common feature of different streptococcal species. Infect Immun 72(2):1192–1194. https://doi.org/10.1128/IAI.72.2.1192-1194.2004
Boman HG, Hultmark D (1987) Cell-free immunity in insects. Annu Rev Microbiol 41:103–126. https://doi.org/10.1146/annurev.mi.41.100187.000535
Boyd WA, Smith MV, Co CA, Pirone JR, Rice JR, Shockley KR, Freedman JH (2016) Developmental effects of the ToxCast™ phase I and phase II chemicals in Caenorhabditis elegans and corresponding responses in zebrafish, rats, and rabbits. Environ Health Perspect 124(5):586–593. https://doi.org/10.1289/ehp.1409645
Brackman G, Breyne K, De Rycke R, Vermote A, Van Nieuwerburgh F, Meyer E, Van Calenbergh S, Coenye T (2016) The quorum sensing inhibitor hamamelitannin increases antibiotic susceptibility of Staphylococcus aureus biofilms by affecting peptidoglycan biosynthesis and eDNA release. Sci Rep 6:20321. https://doi.org/10.1038/srep20321
Briffotaux J, Xu Y, Huang W, Hui Z, Wang X, Gicquel B, Liu S (2022) A hydrazine-hydrazone adamantine compound shows antimycobacterial activity and is a probable inhibitor of MmpL3. Molecules 27(20):7130. https://doi.org/10.3390/molecules27207130
Brown SE, Howard A, Kasprzak AB, Gordon KH, East PD (2009) A peptidomics study reveals the impressive antimicrobial peptide arsenal of the wax moth Galleria mellonella. Insect Biochem Mol Biol 39(11):792–800. https://doi.org/10.1016/j.ibmb.2009.09.004
Brunner M, Derendorf H, Müller M (2005) Microdialysis for in vivo pharmacokinetic/pharmacodynamic characterization of anti-infective drugs. Curr Opin Pharmacol 5(5):495–499. https://doi.org/10.1016/j.coph.2005.04.010
Burt T, Vuong LT, Baker E, Young GC, McCartt AD, Bergstrom M, Sugiyama Y, Combes R (2018) Phase 0, including microdosing approaches: applying the three Rs and increasing the efficiency of human drug development. Altern Lab Anim 46(6):335–346. https://doi.org/10.1177/026119291804600603
Burt T, Yoshida K, Lappin G, Vuong L, John C, de Wildt SN, Sugiyama Y, Rowland M (2016) Microdosing and other phase 0 clinical trials: facilitating translation in drug development. Clin Transl Sci 9(2):74–88. https://doi.org/10.1111/cts.12390
Carbone L (2011) Pain in laboratory animals: the ethical and regulatory imperatives. PLoS One 6(9):e21578 https://doi.org/10.1371/journal.pone.0021578
Castillo Y, Suzuki J, Watanabe K, Shimizu T, Watarai M (2016) Effect of vitamin A on Listeria monocytogenes infection in a silkworm model. PLoS One 11(9):e0163747. https://doi.org/10.1371/journal.pone.0163747
Chen X, Roberts R, Tong W, Liu Z (2022) Tox-GAN: an artificial intelligence approach alternative to animal studies-a case study with toxicogenomics. Toxicol Sci 186(2):242–259. https://doi.org/10.1093/toxsci/kfab157
Cho HS, Lee JH, Cho MH, Lee J (2015) Red wines and flavonoids diminish Staphylococcus aureus virulence with anti-biofilm and anti-hemolytic activities. Biofouling 31(1):1–11. https://doi.org/10.1080/08927014.2014.991319
Choi KG, Wu BC, Lee AH, Baquir B, Hancock REW (2020) Utilizing organoid and air-liquid interface models as a screening method in the development of new host defense peptides. Front Cell Infect Microbiol 10:228. https://doi.org/10.3389/fcimb.2020.00228
Combes RD, Berridge T, Connelly J, Eve MD, Garner RC, Toon S, Wilcox P (2003) Early microdose drug studies in human volunteers can minimise animal testing: proceedings of a workshop organised by Volunteers in Research and Testing. Eur J Pharm Sci 19(1):1–11. https://doi.org/10.1016/s0928-0987(03)00040-x
Conery AL, Larkins-Ford J, Ausubel FM, Kirienko NV (2014) High-throughput screening for novel anti-infectives using a C. elegans pathogenesis model. Curr Protoc Chem Biol 6(1):25–37. https://doi.org/10.1002/9780470559277.ch130160
Danku AE, Dulf EH, Braicu C, Jurj A, Berindan-Neagoe I (2022) Organ-on-a-chip: a survey of technical results and problems. Front Bioeng Biotechnol 10:840674. https://doi.org/10.3389/fbioe.2022.840674
das Chagas Almeida A, Azevedo Rodrigues L, Dos Santos PG, Pereira Aguilar A, Andrade Almeida A, Olavo Ferreira S, Brandão GC, Viana Leite JP, de Oliveira BR (2019) Prenylated flavonoid-enriched fraction from Maclura tinctoria shows biological activity against Staphylococcus aureus and protects Galleria mellonella larvae from bacterial infection. BMC Complement Altern Med 19(1):189. https://doi.org/10.1186/s12906-019-2600-y.PMID:31357964;PMCID:PMC6664575
Deng Y, Du H, Tang M et al (2021) Biosafety assessment of Acinetobacter strains isolated from the Three Gorges Reservoir region in nematode Caenorhabditis elegans. Sci Rep 11:19721. https://doi.org/10.1038/s41598-021-99274-0
Desalermos A, Muhammed M, Glavis-Bloom J, Mylonakis E (2011) Using C. elegans for antimicrobial drug discovery. Expert Opin Drug Discov 6(6):645–652. https://doi.org/10.1517/17460441.2011.573781
Di Blasio S, Clarke M, Hind CK, Asai M, Laurence L, Benvenuti A et al (2023) Bolaamphiphile analogues of 12-bis-THA Cl2 are potent antimicrobial therapeutics with distinct mechanisms of action against bacterial, mycobacterial, and fungal pathogens. mSphere 8(1):e0050822. https://doi.org/10.1128/msphere.00508-22
Dinh H, Semenec L, Kumar SS, Short FL, Cain AK (2021) Microbiology's next top model: Galleria in the molecular age. Pathog Dis 79(2):ftab006. https://doi.org/10.1093/femspd/ftab006
Dodd W, Tang L, Lone JC, Wimberly K, Wu CW, Consalvo C, Wright JE, Pujol N, Choe KP (2018) A damage sensor associated with the cuticle coordinates three core environmental stress responses in Caenorhabditis elegans. Genetics 208(4):1467–1482. https://doi.org/10.1534/genetics.118.300827
Doke SK, Dhawale SC (2015) Alternatives to animal testing: a review. Saudi Pharm J 23(3):223–229. https://doi.org/10.1016/j.jsps.2013.11.002
Durai S, Vigneshwari L, Balamurugan K (2013) Caenorhabditis elegans-based in vivo screening of bioactives from marine sponge-associated bacteria against Vibrio alginolyticus. J Appl Microbiol 115(6):1329–1342. https://doi.org/10.1111/jam.12335
Ekins S, Perryman AL, Clark AM, Reynolds RC, Freundlich JS (2016) Machine learning model analysis and data visualization with small molecules tested in a mouse model of Mycobacterium tuberculosis infection (2014–2015). J Chem Inf Model. 56(7):1332–1343. https://doi.org/10.1021/acs.jcim.6b00004
Elkabti AB, Issi L, Rao RP (2018) Caenorhabditis elegans as a model host to monitor the Candida infection processes. J Fungi (basel) 4(4):123. https://doi.org/10.3390/jof4040123
Ellis JD, Graham JR, Mortensen A (2013) Standard methods for wax moth research. J Apic Res 52:1–17. https://doi.org/10.3896/IBRA.1.52.1.10
Eng SA, Nathan S (2015) Curcumin rescues Caenorhabditis elegans from a Burkholderia pseudomallei infection. Front Microbiol 6:290. https://doi.org/10.3389/fmicb.2015.00290
Esch EW, Bahinski A, Huh D (2015) Organs-on-chips at the frontiers of drug discovery. Nat Rev Drug Discov 14(4):248–260. https://doi.org/10.1038/nrd4539
Everman JL, Ziaie NR, Bechler J, Bermudez LE (2015) Establishing Caenorhabditis elegans as a model for Mycobacterium avium subspecies hominissuis infection and intestinal colonization. Biol Open 4(10):1330–1335. https://doi.org/10.1242/bio.012260
Ewbank JJ, Zugasti O (2011) C. elegans: model host and tool for antimicrobial drug discovery. Dis Model Mech 4(3):300–4. https://doi.org/10.1242/dmm.006684
FDA (2006) Guidance for industry, investigators, and reviewers exploratory IND Studies. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM078933.pdf
Festing S, Wilkinson R (2007) The ethics of animal research. Talking Point on the use of animals in scientific research. EMBO Rep 8(6):526–30. https://doi.org/10.1038/sj.embor.7400993
Franco NH (2013) Animal experiments in biomedical research: a historical perspective. Animals (basel) 3(1):238–273. https://doi.org/10.3390/ani3010238
Garner RC, Lappin G (2006) The phase 0 microdosing concept. Br J Clin Pharmacol 61(4):367–370. https://doi.org/10.1111/j.1365-2125.2006.02575.x
Hamamoto H, Tonoike A, Narushima K, Horie R, Sekimizu K (2009) Silkworm as a model animal to evaluate drug candidate toxicity and metabolism. Comp Biochem Physiol C Toxicol Pharmacol 149(3):334–339. https://doi.org/10.1016/j.cbpc.2008.08.008
Hamamoto H, Urai M, Ishii K, Yasukawa J, Paudel A, Murai M, Kaji T, Kuranaga T, Hamase K, Katsu T, Su J, Adachi T, Uchida R, Tomoda H, Yamada M, Souma M, Kurihara H, Inoue M, Sekimizu K (2015) Lysocin E is a new antibiotic that targets menaquinone in the bacterial membrane. Nat Chem Biol 11(2):127–133. https://doi.org/10.1038/nchembio.1710
Hartung T (2022) Replacing animal testing: how and when? Front Young Minds 10:959496. https://doi.org/10.3389/frym.2022.959496
Hill L, Veli N, Coote PJ (2014) Evaluation of Galleria mellonella larvae for measuring the efficacy and pharmacokinetics of antibiotic therapies against Pseudomonas aeruginosa infection. Int J Antimicrob Agents 43(3):254–261. https://doi.org/10.1016/j.ijantimicag.2013.11.001
Huang X, Xu M, Pan W, Wang M, Wu X, Dai S, Li L, Zeng K (2020) Antimicrobial and immunomodulatory responses of photodynamic therapy in Galleria mellonella model. BMC Microbiol 20(1):196. https://doi.org/10.1186/s12866-020-01882-9
Huh D, Kim HJ, Fraser JP, Shea DE, Khan M, Bahinski A, Hamilton GA, Ingber DE (2013) Microfabrication of human organs-on-chips. Nat Protoc 8(11):2135–2157. https://doi.org/10.1038/nprot.2013.137
Hunt PR (2017) The C. elegans model in toxicity testing. J Appl Toxicol 37(1):50–59. https://doi.org/10.1002/jat.3357
Hunt PR, Camacho JA, Sprando RL (2020) Caenorhabditis elegans for predictive toxicology. Curr Opin Toxicol 23–24:23–28. https://doi.org/10.1016/j.cotox.2020.02.004
Hunt PR, Olejnik N, Sprando RL (2012) Toxicity ranking of heavy metals with screening method using adult Caenorhabditis elegans and propidium iodide replicates toxicity ranking in rat. Food Chem Toxicol 50(9):3280–3290. https://doi.org/10.1016/j.fct.2012.06.051
Ibánez-Peinado D, Pina-Pérez C, García-Carrión G, Martínez A, Rodrigo D (2020) In vivo antimicrobial activity assessment of a cauliflower by-product extract against Salmonella Typhimurium. Front Sustain Food Syst 4:8. https://doi.org/10.3389/fsufs.2020.00008
Ignasiak K, Maxwell A (2017) Galleria mellonella (greater wax moth) larvae as a model for antibiotic susceptibility testing and acute toxicity trials. BMC Res Notes 10(1):428. https://doi.org/10.1186/s13104-017-2757-8
Ingber DE (2023) Human organs-on-chips for disease modelling, drug development and personalized medicine. Nat Rev Genet 23:467–491. https://doi.org/10.1038/s41576-022-00466-9
Insua JL, Llobet E, Moranta D, Pérez-Gutiérrez C, Tomás A, Garmendia J, Bengoechea JA (2013) Modelling Klebsiella pneumoniae pathogenesis by infection of the wax moth Galleria mellonella. Infect Immun 81(10):3552–3565. https://doi.org/10.1128/IAI.00391-13
Irazoqui JE, Urbach JM, Ausubel FM (2010) Evolution of host innate defence: insights from Caenorhabditis elegans and primitive invertebrates. Nat Rev Immunol 10(1):47–58. https://doi.org/10.1038/nri2689
Jayamani E, Rajamuthiah R, Larkins-Ford J, Fuchs BB, Conery AL, Vilcinskas A, Ausubel FM, Mylonakis E (2015) Insect-derived cecropins display activity against Acinetobacter baumannii in a whole-animal high-throughput Caenorhabditis elegans model. Antimicrob Agents Chemother 59(3):1728–1737. https://doi.org/10.1128/AAC.04198-14
Jayamani E, Tharmalingam N, Rajamuthiah R, Coleman JJ, Kim W, Okoli I, Hernandez AM, Lee K, Nau GJ, Ausubel FM, Mylonakis E (2017) Characterization of a Francisella tularensis-Caenorhabditis elegans pathosystem for the evaluation of therapeutic compounds. Antimicrob Agents Chemother 61(9):e00310-e317. https://doi.org/10.1128/AAC.00310-17
Jeon J, Park JH, Yong D (2019) Efficacy of bacteriophage treatment against carbapenem-resistant Acinetobacter baumannii in Galleria mellonella larvae and a mouse model of acute pneumonia. BMC Microbiol 19(1):70. https://doi.org/10.1186/s12866-019-1443-5
Johnstone IL (2000) Cuticle collagen genes. Expression in Caenorhabditis Elegans Trends Genet 16(1):21–27. https://doi.org/10.1016/s0168-9525(99)01857-0
Joshua GWP, Karlyshev AV, Smith MP, Isherwood KE, Titball RW, Wren BW (2003) A Caenorhabditis elegans model of Yersinia infection: biofilm formation on a biotic surface. Microbiology (reading) 149(Pt 11):3221–3229. https://doi.org/10.1099/mic.0.26475-0
Kaito C, Akimitsu N, Watanabe H, Sekimizu K (2002) Silkworm larvae as an animal model of bacterial infection pathogenic to humans. Microb Pathog 32(4):183–190. https://doi.org/10.1006/mpat.2002.0494
Kaito C, Murakami K, Imai L, Furuta K (2020) Animal infection models using non-mammals. Microbiol Immunol 64:585–592. https://doi.org/10.1111/1348-0421.12834
Kaskatepe B, Ozturk S (2023) Assessment of synergistic activity of rhamnolipid and linezolid against methicillin-resistant Staphylococcus aureus in-vitro and in-vivo with Galleria mellonella larvae model. Microb Pathog 174:105945. https://doi.org/10.1016/j.micpath.2022.105945
Kay S, Edwards J, Brown J, Dixon R (2019) Galleria mellonella infection model identifies both high and low lethality of Clostridium perfringens toxigenic strains and their response to antimicrobials. Front Microbiol 10:1281. https://doi.org/10.3389/fmicb.2019.01281
Khader R, Tharmalingam N, Mishra B, Felix L, Ausubel FM, Kelso MJ, Mylonakis E (2020) Characterization of five novel anti-MRSA compounds identified using a whole-animal Caenorhabditis elegans/Galleria mellonella sequential-screening approach. Antibiotics (basel) 9(8):449. https://doi.org/10.3390/antibiotics9080449
Kim DH, Feinbaum R, Alloing G, Emerson FE, Garsin DA, Inoue H, Tanaka-Hino M, Hisamoto N, Matsumoto K, Tan MW, Ausubel FM (2002) A conserved p38 MAP kinase pathway in Caenorhabditis elegans innate immunity. Science 297(5581):623–626. https://doi.org/10.1126/science.1073759
Kim CH, Lee JH, Kim I, Seo SJ, Son SM, Lee KY, Lee IH (2004a) Purification and cDNA cloning of a cecropin-like peptide from the great wax moth, Galleria mellonella. Mol Cells 17:262–266
Kim HJ, Lee J, Choi JH, Bahinski A, Ingber DE (2004b) Co-culture of living microbiome with microengineered human intestinal villi in a gut-on-a-chip microfluidic device. J vis Exp 114:54344. https://doi.org/10.3791/54344
Kim J, Hegde M, Jayaraman A (2010) Microfluidic co-culture of epithelial cells and bacteria for investigating soluble signal-mediated interactions. J vis Exp 38:1749. https://doi.org/10.3791/1749
Kim W, Conery AL, Rajamuthiah R, Fuchs BB, Ausubel FM, Mylonakis E (2015) Identification of an antimicrobial agent effective against methicillin-resistant Staphylococcus aureus persisters using a fluorescence-based screening strategy. PLoS One 10(6):e0127640. https://doi.org/10.1371/journal.pone.0127640
Kim HJ, Lee J, Choi JH, Bahinski A, Ingber DE (2016) Co-culture of living microbiome with microengineered human intestinal villi in a gut-on-a-chip microfluidic device. J Vis Exp 114:54344. https://doi.org/10.3791/54344
Kim W, Hendricks GL, Lee K, Mylonakis E (2017) An update on the use of C. elegans for preclinical drug discovery: screening and identifying anti-infective drugs. Expert Opin Drug Discov 12(6):625–633. https://doi.org/10.1080/17460441.2017.1319358
Kim JJ, Ellett F, Thomas CN, Jalali F, Anderson RR, Irimia D, Raff AB (2019) A microscale, full-thickness, human skin on a chip assay simulating neutrophil responses to skin infection and antibiotic treatments. Lab Chip 19(18):3094–3103. https://doi.org/10.1039/c9lc00399a
Kim SM, Escorbar I, Lee K, Fuchs BB, Mylonakis E, Kim W (2020) Anti-MRSA agent discovery using Caenorhabditis elegans-based high-throughput screening. J Microbiol 58(6):431–444. https://doi.org/10.1007/s12275-020-0163-8
Kimura H, Sakai Y, Fujii T (2018) Organ/body-on-a-chip based on microfluidic technology for drug discovery. Drug Metab Pharmacokinet 33(1):43–48. https://doi.org/10.1016/j.dmpk.2017.11.003
Kirienko NV, Kirienko DR, Larkins-Ford J, Wählby C, Ruvkun G, Ausubel FM (2013) Pseudomonas aeruginosa disrupts Caenorhabditis elegans iron homeostasis, causing a hypoxic response and death. Cell Host Microbe 13(4):406–416. https://doi.org/10.1016/j.chom.2013.03.003
Kochi Y, Miyashita A, Tsuchiya K, Mitsuyama M, Sekimizu K, Kaito C (2016) A human pathogenic bacterial infection model using the two-spotted cricket, Gryllus bimaculatus. FEMS Microbiol Lett 363(15):fnw163. https://doi.org/10.1093/femsle/fnw163
Kong C, Eng SA, Lim MP, Nathan S (2016) Beyond traditional antimicrobials: a Caenorhabditis elegans model for discovery of novel anti-infectives. Front Microbiol 7:1956. https://doi.org/10.3389/fmicb.2016.01956
Konkel ME, Tilly K (2000) Temperature-regulated expression of bacterial virulence genes. Microbes Infect 2:157–166. https://doi.org/10.1016/S1286-4579(00)00272-0
Kropp PA, Bauer R, Zafra I, Graham C, Golden A (2021) Caenorhabditis elegans for rare disease modelling and drug discovery: strategies and strengths. Dis Model Mech 14(8):dmm049010. https://doi.org/10.1242/dmm.049010
Kummar S, Rubinstein L, Kinders R, Parchment RE, Gutierrez ME, Murgo AJ, Ji J, Mroczkowski B, Pickeral OK, Simpson M, Hollingshead M, Yang SX, Helman L, Wiltrout R, Collins J, Tomaszewski JE, Doroshow JH (2008) Phase 0 clinical trials: conceptions and misconceptions. Cancer J 14(3):133–137. https://doi.org/10.1097/PPO.0b013e318172d6f3
Kurokawa K, Kaito C, Sekimizu K (2007) Two-component signalling in the virulence of Staphylococcus aureus: a silkworm larvae pathogenic agent infection model of virulence. Methods Enzymol 422:233–244. https://doi.org/10.1016/S0076-6879(06)22011-1
Kwadha CA, Ong’amo GO, Ndegwa PN, Raina SK, Fombong AT (2017) The biology and control of the greater wax moth. Galleria Mellonella inSects 8(2):61. https://doi.org/10.3390/insects8020061
Kyriakakis E, Markaki M, Tavernarakis N (2014) Caenorhabditis elegans as a model for cancer research. Mol Cell Oncol 2(2):e975027. https://doi.org/10.4161/23723556.2014.975027.
Lappin G, Garner RC (2003) Big physics, small doses: the use of AMS and PET in human microdosing of development drugs. Nat Rev Drug Discov 2(3):233–240. https://doi.org/10.1038/nrd1037
Lappin G, Garner RC (2008) The utility of microdosing over the past 5 years. Expert Opin Drug Metab Toxicol 4(12):1499–1506. https://doi.org/10.1517/17425250802531767
Lee JH, Kim YG, Cho HS, Ryu SY, Cho MH, Lee J (2014) Coumarins reduce biofilm formation and the virulence of Escherichia coli O157:H7. Phytomedicine 21(8–9):1037–1042. https://doi.org/10.1016/j.phymed.2014.04.008
Leung CM, deHan P, Ronaldson-Bouchard K, Kim GA, Ko J et al (2022) A guide to the organ-on-a-chip. Nature Reviews Methods Primers 2:33. https://doi.org/10.1038/s43586-022-00118-6
Li J, Chen J, Bai H, Wang H, Hao S, Ding Y, Peng B, Zhang J, Li L, Huang W (2022a) An overview of organs-on-chips based on deep learning. research (Wash D C). 2022:9869518. https://doi.org/10.34133/2022/9869518
Li Y, Spiropoulos J, Cooley W, Khara JS, Gladstone CA, Asai M, Bossé JT, Robertson BD, Newton SM, Langford PR (2018) Galleria mellonella - a novel infection model for the Mycobacterium tuberculosis complex. Virulence 9(1):1126–1137. https://doi.org/10.1080/21505594.2018.1491255
Li Z, Hui J, Yang P, Mao H (2022b) Microfluidic organ-on-a-chip system for disease modeling and drug development. Biosensors (basel) 12(6):370. https://doi.org/10.3390/bios12060370
Liu Y, Leung SSY, Guo Y, Zhao L, Jiang N, Mi L, Li P, Wang C, Qin Y, Mi Z, Bai C, Gao Z (2019) The capsule depolymerase Dpo48 rescues Galleria mellonella and mice from Acinetobacter baumannii systemic infections. Front Microbiol 10:545. https://doi.org/10.3389/fmicb.2019.00545
Loh JM, Adenwalla N, Wiles S (2013) Proft T (2013) Galleria mellonella larvae as an infection model for group A streptococcus. Virulence 4:419–428. https://doi.org/10.4161/viru.24930
Long NP, Kang JS, Kim HM (2023) Caenorhabditis elegans: a model organism in the toxicity assessment of environmental pollutants. Environ Sci Pollut Res Int 30(14):39273–39287. https://doi.org/10.1007/s11356-023-25675-5
Maguire R, Duggan O, Kavanagh K (2016) Evaluation of Galleria mellonella larvae as an in vivo model for assessing the relative toxicity of food preservative agents. Cell Biol Toxicol 32(3):209–216. https://doi.org/10.1007/s10565-016-9329-x
Markaki M, Tavernarakis N (2020) Caenorhabditis elegans as a model system for human diseases. Curr Opin Biotechnol 63:118–125. https://doi.org/10.1016/j.copbio.2019.12.011
Materazzi A, Bottai D, Campobasso C, Klatt AB, Cesta N, De Masi M, Trampuz A, Tavanti A, Di Luca M (2022) Phage-based control of methicillin resistant Staphylococcus aureus in a Galleria mellonella model of implant-associated infection. Int J Mol Sci 23(23):14514. https://doi.org/10.3390/ijms232314514
McCloskey AP, Lee M, Megaw J, McEvoy J, Coulter SM, Pentlavalli S, Laverty G (2019) Investigating the in vivo antimicrobial activity of a self-assembling peptide hydrogel using a Galleria mellonella infection model. ACS Omega 4(2):2584–2589. https://doi.org/10.1021/acsomega.8b03578
Megaw J, Thompson TP, Lafferty RA, Gilmore BF (2015) Galleria mellonella as a novel in vivo model for assessment of the toxicity of 1-alkyl-3-methylimidazolium chloride ionic liquids. Chemosphere 139:197–201. https://doi.org/10.1016/j.chemosphere.2015.06.026
Ménard G, Rouillon A, Ghukasyan G, Emily M, Felden B, Donnio PY (2021) Galleria mellonella larvae as an infection model to investigate sRNA-mediated pathogenesis in Staphylococcus aureus. Front Cell Infect Microbiol 11:631710. https://doi.org/10.3389/fcimb.2021.631710
Meneely PM, Dahlberg CL, Rose JK (2019) Working with worms: Caenorhabditis elegans as a model organism. Curr Protoc Essent Lab Tech 19:e35
Meng X, Zhu F, Chen K (2017) Silkworm: a promising model organism in life science. J Insect Sci 17(5):97. https://doi.org/10.1093/jisesa/iex064
Mito T, Noji S (2008) The two-spotted cricket Gryllus bimaculatus: an emerging model for developmental and regeneration studies. CSH Protoc 2008:pdb.emo110. https://doi.org/10.1101/pdb.emo110
Miyazaki S, Matsumoto Y, Sekimizu K, Kaito C (2012) Evaluation of Staphylococcus aureus virulence factors using a silkworm model. FEMS Microbiol Lett 326:116–124
Mohanta MK, Saha AK, Saleh DK, Islam MS, Mannan KS, Fakruddin M (2015) Characterization of Klebsiella granulomatis pathogenic to silkworm, Bombyx mori L. 3 Biotech 5(4):577–583. https://doi.org/10.1007/s13205-014-0255-4
Montali A, Berini F, Saviane A, Cappellozza S, Marinelli F, Tettamanti G (2022) A Bombyx mori infection model for screening antibiotics against Staphylococcus epidermidis. InSects 13(8):748. https://doi.org/10.3390/insects13080748
Moy TI, Conery AL, Larkins-Ford J, Wu G, Mazitschek R, Casadei G, Lewis K, Carpenter AE, Ausubel FM (2009) High-throughput screen for novel antimicrobials using a whole animal infection model. ACS Chem Biol 4(7):527–533. https://doi.org/10.1021/cb900084v
Muhammed M, Coleman JJ, Mylonakis E (2012) Caenorhabditis elegans: a nematode infection model for pathogenic fungi. Methods Mol Biol 845:447–454. https://doi.org/10.1007/978-1-61779-539-8_31
Mylonakis E, Moreno R, El Khoury JB, Idnurm A, Heitman J, Calderwood SB, Ausubel FM, Diener A (2005) Galleria mellonella as a model system to study Cryptococcus neoformans pathogenesis. Infect Immun 73(7):3842–3850. https://doi.org/10.1128/IAI.73.7.3842-3850.2005
Nale JY, Chutia M, Carr P, Hickenbotham PT, Clokie MR (2016) “Get in early”; biofilm and wax moth (Galleria mellonella) models reveal new insights into the therapeutic potential of Clostridium difficile bacteriophages. Front Microbiol 7:1383. https://doi.org/10.3389/fmicb.2016.01383
Nale JY, Vinner GK, Lopez VC, Thanki AM, Phothaworn P, Thiennimitr P, Garcia A, AbuOun M, Anjum MF, Korbsrisate S, Galyov EE, Malik DJ, Clokie MRJ (2021) An optimized bacteriophage cocktail can effectively control Salmonella in vitro and in Galleria mellonella. Front Microbiol 11:609955. https://doi.org/10.3389/fmicb.2020.609955
Neethirajan S, Karig D, Kumar A, Mukherjee P et al (2012) Biofilms in microfluidic devices. Encyclopedia of nanotechnology. Springer Netherlands, pp 213–219. https://doi.org/10.1007/978-90-481-9751-4_427
Oesterreicher Z, Eberl S, Wulkersdorfer B, Matzneller P, Eder C, van Duijn E, Vaes WHJ, Reiter B, Stimpfl T, Jäger W, Nussbaumer-Proell A, Marhofer D, Marhofer P, Langer O, Zeitlinger M (2022) Microdosing as a potential tool to enhance clinical development of novel antibiotics: a tissue and plasma PK feasibility study with ciprofloxacin. Clin Pharmacokinet 61(5):697–707. https://doi.org/10.1007/s40262-021-01091-1
Panthee S, Paudel A, Hamamoto H, Sekimizu K (2017) Advantages of the silkworm as an animal model for developing novel antimicrobial agents. Front Microbiol 8:373. https://doi.org/10.3389/fmicb.2017.00373
Paudel A, Furuta Y, Higashi H (2021) Silkworm model for Bacillus anthracis infection and virulence determination. Virulence 12(1):2285–2295. https://doi.org/10.1080/21505594.2021.1965830
Peleg AY, Jara S, Monga D, Eliopoulos GM, Moellering RC Jr, Mylonakis E (2009) Galleria mellonella as a model system to study Acinetobacter baumannii pathogenesis and therapeutics. Antimicrob Agents Chemother 53:2605–2609
Peterson ND, Pukkila-Worley R (2018) Caenorhabditis elegans in high-throughput screens for anti-infective compounds. Curr Opin Immunol 54:59–65. https://doi.org/10.1016/j.coi.2018.06.003
Piatek M, Sheehan G, Kavanagh K (2021) Galleria mellonella: the versatile host for drug discovery, in vivo toxicity testing and characterising host-pathogen interactions. Antibiotics (basel) 10(12):1545. https://doi.org/10.3390/antibiotics10121545
Plebani R, Potla R, Soong M, Bai H, Izadifar Z, Jiang A, Travis RN, Belgur C, Dinis A, Cartwright MJ, Prantil-Baun R, Jolly P, Gilpin SE, Romano M, Ingber DE (2022) Modeling pulmonary cystic fibrosis in a human lung airway-on-a-chip. J Cyst Fibros 21(4):606–615. https://doi.org/10.1016/j.jcf.2021.10.004
Prithiviraj B, Bais HP, Weir T, Suresh B, Najarro EH, Dayakar BV, Schweizer HP, Vivanco JM (2005) Down regulation of virulence factors of Pseudomonas aeruginosa by salicylic acid attenuates its virulence on Arabidopsis thaliana and Caenorhabditis elegans. Infect Immun 73(9):5319–5328. https://doi.org/10.1128/IAI.73.9.5319-5328.2005
Rajamuthiah R, Fuchs BB, Jayamani E, Kim Y, Larkins-Ford J, Conery A, Ausubel FM, Mylonakis E (2014) Whole animal automated platform for drug discovery against multi-drug resistant Staphylococcus aureus. PLoS One 9(2):e89189. https://doi.org/10.1371/journal.pone.0089189
Rajamuthiah R, Jayamani E, Majed H, Conery AL, Kim W, Kwon B, Fuchs BB, Kelso MJ, Ausubel FM, Mylonakis E (2015) Antibacterial properties of 3-(phenylsulfonyl)-2-pyrazinecarbonitrile. Bioorg Med Chem Lett 25(22):5203–5207. https://doi.org/10.1016/j.bmcl.2015.09.066
Ramarao N, Nielsen-Leroux C, Lereclus D (2012) The insect Galleria mellonella as a powerful infection model to investigate bacterial pathogenesis. J Vis Exp 70:e4392. https://doi.org/10.3791/4392
Ranganatha N, Kuppast IJ (2012) A review on alternatives to animal testing methods in drug development. Int J Pharm Pharm Sci 4:28–32
Rani PU, Naidu MU (2008) Phase 0 - Microdosing strategy in clinical trials. Indian J Pharmacol 40(6):240–242. https://doi.org/10.4103/0253-7613.45147
Rudrappa T, Bais HP (2008) Curcumin, a known phenolic from Curcuma longa, attenuates the virulence of Pseudomonas aeruginosa PAO1 in whole plant and animal pathogenicity models. J Agric Food Chem 56(6):1955–1962. https://doi.org/10.1021/jf072591j
Rusche B (2003) The 3Rs and animal welfare - conflict or the way forward? ALTEX 20(Suppl 1):63–76
Rwegasila E, Mubofu EB, Nyandoro SS, Erasto P, Munissi JJ (2016) Preparation, characterization and in vivo antimycobacterial studies of panchovillin-chitosan nanocomposites. Int J Mol Sci 17(10):1559. https://doi.org/10.3390/ijms17101559
Satta S, Rockwood SJ, Wang K, Wang S, Mozneb M, Arzt M, Hsiai TK, Sharma A (2023) Microfluidic organ-chips and stem cell models in the fight against COVID-19. Circ Res 132(10):1405–1424. https://doi.org/10.1161/CIRCRESAHA.122.321877
Shen C, Yang H, She W, Meng Q (2023) A microfluidic lung-on-a-chip based on biomimetic hydrogel membrane. Biotechnol Bioeng 120(7):2027–2038. https://doi.org/10.1002/bit.28426
Sifri CD, Begun J, Ausubel FM (2005) The worm has turned–microbial virulence modelled in Caenorhabditis elegans. Trends Microbiol 13:119–127
Sifri CD, Begun J, Ausubel FM, Calderwood SB (2003) Caenorhabditis elegans as a model host for Staphylococcus aureus pathogenesis. Infect Immun 71(4):2208–2217. https://doi.org/10.1128/IAI.71.4.2208-2217.2003
Simpson C, Lee SS, Lee CS et al (2018) Microfluidics: an untapped resource in viral diagnostics and viral cell biology. Curr Clin Micro 5:245–251. https://doi.org/10.1007/s40588-018-0105-y
Singh D, Mathur A, Arora S, Roy S, Mahindroo N (2022) Journey of organ on a chip technology and its role in future healthcare scenario. Appl Surf Sci Adv 9:100246. https://doi.org/10.1016/j.apsadv.2022.100246
Singh VK, Seed TM (2021) How necessary are animal models for modern drug discovery? Expert Opin Drug Discov 16(12):1391–1397. https://doi.org/10.1080/17460441.2021.1972255
Sivaranjani M, Gowrishankar S, Kamaladevi A, Pandian SK, Balamurugan K, Ravi AV (2016) Morin inhibits biofilm production and reduces the virulence of Listeria monocytogenes - an in vitro and in vivo approach. Int J Food Microbiol 237:73–82. https://doi.org/10.1016/j.ijfoodmicro.2016.08.021
Smith T (1965) External morphology of the larva, pupa, and adult of the wax moth, Galleria mellonella L. J Kans Entomol Soc 38:287–310
Smitten K, Southam HM, Fairbanks S, Graf A, Chauvet A, Thomas JA (2023) Clearing an ESKAPE pathogen in a model organism; a polypyridyl ruthenium(II) complex theranostic that treats a resistant Acinetobacter baumannii infection in Galleria mellonella. Chemistry 29(11):e202203555. https://doi.org/10.1002/chem.02203555
Smoot LM, Smoot JC, Graham MR, Somerville GA, Sturdevant DE, Migliaccio CA, Sylva GL, Musser JM (2001) Global differential gene expression in response to growth temperature alteration in group A Streptococcus. Proc Natl Acad Sci USA 98:10416–10421. https://doi.org/10.1073/pnas.191267598
Sosa-Hernández JE, Villalba-Rodríguez AM, Romero-Castillo KD, Aguilar-Aguila-Isaías MA, García-Reyes IE, Hernández-Antonio A, Ahmed I, Sharma A, Parra-Saldívar R, Iqbal HMN (2018) Organs-on-a-chip module: a review from the development and applications perspective. Micromachines (basel) 9(10):536. https://doi.org/10.3390/mi9100536
Suehiro Y, Nomura, R, Matayoshi S et al (2022) Evaluation of the collagen-binding properties and virulence of killed Streptococcus mutans in a silkworm model. Sci Rep 12: 2800. https://doi.org/10.1038/s41598-022-06345-x
Sunildutt N, Parihar P, Chethikkattuveli Salih AR, Lee SH, Choi KH (2023) Revolutionizing drug development: harnessing the potential of organ-on-chip technology for disease modeling and drug discovery. Front Pharmacol 14:1139229. https://doi.org/10.3389/fphar.2023.1139229
Suzuki J, Uda A, Watanabe K et al (2016) Symbiosis with Francisella tularensis provides resistance to pathogens in the silkworm. Sci Rep 6:31476. https://doi.org/10.1038/srep31476
Tan MW, Mahajan-Miklos S, Ausubel FM (1999a) Killing of Caenorhabditis elegans by Pseudomonas aeruginosa used to model mammalian bacterial pathogenesis. Proc Natl Acad Sci USA 96(2):715–720. https://doi.org/10.1073/pnas.96.2.715
Tan MW, Rahme LG, Sternberg JA, Tompkins RG, Ausubel FM (1999b) Pseudomonas aeruginosa killing of Caenorhabditis elegans used to identify P. aeruginosa virulence factors. Proc Natl Acad Sci USA 96(5):2408–2413. https://doi.org/10.1073/pnas.96.5.2408
Tang PC, Eriksson O, Sjögren J, Fatsis-Kavalopoulos N, Kreuger J, Andersson DI (2022) A microfluidic chip for studies of the dynamics of antibiotic resistance selection in bacterial biofilms. Front Cell Infect Microbiol 12:896149. https://doi.org/10.3389/fcimb.2022.896149
Tao Y, Duma L, Rossez Y (2021) Galleria mellonella as a good model to study Acinetobacter baumannii pathogenesis. Pathogens. 10(11):1483. https://doi.org/10.3390/pathogens10111483
Taylor K, Alvarez LR (2019) An estimate of the number of animals used for scientific purposes worldwide in 2015. Altern Lab Anim 47(5–6):196–213. https://doi.org/10.1177/0261192919899853
Ten KE, Muzahid NH, Rahman S, Tan HS (2023) Use of the waxworm Galleria mellonella larvae as an infection model to study Acinetobacter baumannii. PLoS One. Apr 5 18(4):e0283960. https://doi.org/10.1371/journal.pone.0283960
Terry J, Neethirajan S (2014) A novel microfluidic wound model for testing antimicrobial agents against Staphylococcus pseudintermedius biofilms. J Nanobiotechnology 12:1. https://doi.org/10.1186/1477-3155-12-1
Thacker VV, Dhar N, Sharma K, Barrile R, Karalis K, McKinney JD (2020) A lung-on-chip model of early Mycobacterium tuberculosis infection reveals an essential role for alveolar epithelial cells in controlling bacterial growth. Elife 9:e59961. https://doi.org/10.7554/eLife.59961
Thieme L, Hartung A, Makarewicz O, Pletz MW (2020) In vivo synergism of ampicillin, gentamicin, ceftaroline and ceftriaxone against Enterococcus faecalis assessed in the Galleria mellonella infection model. J Antimicrob Chemother 75(8):2173–2181. https://doi.org/10.1093/jac/dkaa129
Thomaz L, Gustavo de Almeida L, Silva FRO, Cortez M, Taborda CP, Spira B (2020) In vivo activity of silver nanoparticles against Pseudomonas aeruginosa infection in Galleria mellonella. Front Microbiol 11:582107. https://doi.org/10.3389/fmicb.2020.582107
Tovaglieri A, Sontheimer-Phelps A, Geirnaert A, Prantil-Baun R, Camacho DM, Chou DB, Jalili-Firoozinezhad S, de Wouters T, Kasendra M, Super M, Cartwright MJ, Richmond CA, Breault DT, Lacroix C, Ingber D (2019) Species-specific enhancement of enterohemorrhagic E. coli pathogenesis mediated by microbiome metabolites. Microbiome 7(1):43. https://doi.org/10.1186/s40168-019-0650-5
Tsai CJ, Loh JM, Proft T (2016) Galleria mellonella infection models for the study of bacterial diseases and for antimicrobial drug testing. Virulence 7(3):214–229. https://doi.org/10.1080/21505594.2015.1135289
Usui K, Miyazaki S, Kaito C, Sekimizu K (2009) Purification of a soil bacteria exotoxin using silkworm toxicity to measure specific activity. Microb Pathog 46(2):59–62. https://doi.org/10.1016/j.micpath.2008.10.010
Usui K, Nishida S, Sugita T, Ueki T, Matsumoto Y, Okumura H, Sekimizu K (2016) Acute oral toxicity test of chemical compounds in silkworms. Drug Discov Ther 10(1):57–61. https://doi.org/10.5582/ddt.2016.01025
van Berlo D, van de Steeg E, Amirabadi HE, Masereeuw R (2021) The potential of multi-organ-on-chip models for assessment of drug disposition as alternative to animal testing. Curr Opin Toxicol 27:8–17. https://doi.org/10.1016/j.cotox.2021.05.001
Wählby C, Kamentsky L, Liu ZH, Riklin-Raviv T, Conery AL, O'Rourke EJ, Sokolnicki KL, Visvikis O, Ljosa V, Irazoqui JE, Golland P, Ruvkun G, Ausubel FM, Carpenter AE (2012) An image analysis toolbox for high-throughput C. elegans assays. Nat Methods 9(7):714–6. https://doi.org/10.1038/nmeth.1984
Wang X, Hong XZ, Li YW, Li Y, Wang J, Chen P, Liu BF (2022) Microfluidics-based strategies for molecular diagnostics of infectious diseases. Mil Med Res 9(1):11. https://doi.org/10.1186/s40779-022-00374-3
Watts G (2007) Animal testing: is it worth it? BMJ 334(7586):182–184. https://doi.org/10.1136/bmj.39058.469491.68
Williams PL, Dusenbery DB (1988) Using the nematode Caenorhabditis elegans to predict mammalian acute lethality to metallic salts. Toxicol Ind Health 4(4):469–478. https://doi.org/10.1177/074823378800400406
World Economic Forum (2021) Top 10 emerging technologies of 2021. https://www.weforum.org/reports/top-10-emerging-technologies-of-2021/
Wu Q, Liu J, Wang X, Feng L, Wu J, Zhu X, Wen W, Gong X (2020) Organ-on-a-chip: recent breakthroughs and future prospects. Biomed Eng Online 19:9. https://doi.org/10.1186/s12938-020-0752-0
Wu BC, Haney EF, Akhoundsadegh N, Pletzer D, Trimble MJ, Adriaans AE, Nibbering PH, Hancock REW (2021) Human organoid biofilm model for assessing antibiofilm activity of novel agents. NPJ Biofilms Microbiomes 7(1):8. https://doi.org/10.1038/s41522-020-00182-4
Wu BC, Blimkie TM, Haney EF, Falsafi R, Akhoundsadegh N, Hancock REW (2022) Host response of human epidermis to methicillin-resistant Staphylococcus aureus biofilm infection and synthetic antibiofilm peptide treatment. Cells 11(21):3459. https://doi.org/10.3390/cells11213459
Xiong H, Pears C, Woollard A (2017) An enhanced C. elegans based platform for toxicity assessment. Sci Rep 7(1):9839. https://doi.org/10.1038/s41598-017-10454-3
Yagi A, Uchida R, Hamamoto H, Sekimizu K, Kimura KI, Tomoda H (2017) Anti-mycobacterium activity of microbial peptides in a silkworm infection model with Mycobacterium smegmatis. J Antibiot (tokyo) 70(5):685–690. https://doi.org/10.1038/ja.2017.23
Yang J, Zheng M, Yang F, Zhang X, Yin W, Liu X, Jun Zhang G, Chen Z (2018) Pseudomonas aeruginosa infected nematode-on-a-chip model array for antibacterials screening. Sens Actuators, B Chem 275:373–381. https://doi.org/10.1016/j.snb.2018.08.062
Yun B, Oh S, Song M, Hong YS, Park S, Park DJ, Griffiths MW, Oh S (2015) Inhibitory effect of epigallocatechin gallate on the virulence of Clostridium difficile PCR ribotype 027. J Food Sci 80(12):M2925–M2931. https://doi.org/10.1111/1750-3841.13145
Zhang F, Berg M, Dierking K, Félix MA, Shapira M, Samuel BS, Schulenburg H (2017) Caenorhabditis elegans as a model for microbiome research. Front Microbiol 8:485. https://doi.org/10.3389/fmicb.2017.00485
Zhang S, Li F, Zhou T, Wang G, Li Z (2020) Caenorhabditis elegans as a useful model for studying aging mutations. Front Endocrinol (Lausanne) 11:554994. https://doi.org/10.3389/fendo.2020.554994
Zheng F, Fu F, Cheng Y, Wang C, Zhao Y, Gu Z (2016) Organ-on-a-chip systems: microengineering to biomimic living systems. Small 12(17):2253–2282. https://doi.org/10.1002/smll.201503208
Zommiti M, Connil N, Tahrioui A, Groboillot A, Barbey C, Konto-Ghiorghi Y, Lesouhaitier O, Chevalier S, Feuilloley MGJ (2022) Organs-on-chips platforms are everywhere: a zoom on biomedical investigation. Bioengineering (basel) 9(11):646. https://doi.org/10.3390/bioengineering9110646
Zurlo J, Rudacille D, Goldberg AM (1996) The three Rs: the way forward. Environ Health Perspect 104(8):878–880. https://doi.org/10.1289/ehp.96104878
Author information
Authors and Affiliations
Contributions
CH, WY: literature search, data collection and extraction, draft writing, editing, and approval of the final manuscript.
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Hu, C., Yang, W. Alternatives to animal models to study bacterial infections. Folia Microbiol 68, 703–739 (2023). https://doi.org/10.1007/s12223-023-01084-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12223-023-01084-6